Guess which ASX healthcare stock is rocketing 110% on US product launch

Shareholders of this stock are smiling on Wednesday. Why is it rocketing?

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Acrux Ltd (ASX: ACR) shares are avoiding the market weakness and rocketing higher on Wednesday.

In morning trade, the ASX healthcare stock was up as much as 110% to 9.9 cents.

To put that into context, a $10,000 investment yesterday afternoon would have grown to be worth $21,000 in less than a day.

The topical pharmaceuticals products developer's shares have eased back a touch since then but remain up 70% to 8 cents at the time of writing.

Why is this ASX healthcare stock rocketing?

Investors have been scrambling to buy the company's shares this morning after it announced the launch of a new product in the United States market.

According to the release, Acrux and its partner TruPharma have launched a generic version of Dapsone 5% Gel.

Dapsone 5% Gel is a prescription medicine which is used on skin (topical) to treat acne vulgaris. Annual market sales for Dapsone 5% Gel products for the 12 months ending October 2023 exceeded US$15 million according to data from IQVIA.

The ASX healthcare stock's CEO and managing director, Michael Kotsanis, was pleased with the news. He said:

We are excited to partner with TruPharma to launch this topical prescription product in the United States. This is another product from the Acrux pipeline that is being commercialised. We look forward to announcing additional regulatory approvals and launches in the future.

What else is in the pipeline?

As mentioned above, the company is working towards additional regulatory approvals and launches.

This includes its Nitroglycerin 0.4% Ointment, which was accepted for review by the FDA in July 2023. This product treats moderate to severe pain associated with chronic anal fissure and has an annual addressable market of US$21.6 million according to IQVIA.

Another product in the pipeline is a generic version of cold sore treatment Acyclovir Cream, 5%. The reference listed drug for this treatment is Zovirax Cream, 5%, which is marketed by Bausch Health in the United States. The annual addressable market for the product exceeds US$29 million according to IQVIA data.

In total, it currently has three products under review by the FDA and seven products in development. But management isn't resting on its laurels. A further two topical generic projects have been identified for commencement in 2024 and thereafter two new topical generic projects are intended to be added each year.

Despite today's impressive gain, the ASX healthcare stock is only up 33% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »